Navigation Links
Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinson's Disease
Date:7/29/2008

Gene silencing techniques and induced pluripotent stem cell technology are among the cutting-edge approaches to Parkinson's drug development funded through The Michael J. Fox Foundation's Rapid Response Innovation Awards 2008. As part of its mission to drive transformative treatments and a cure for PD, the Foundation has awarded $1.1 million for 15 high-risk, high-reward Parkinson's disease research projects under the initiative in the first half of the year. Applications are still being accepted, and a total of $2 million in Rapid Response awards is expected by year's end.

Rapid Response helps keep new and novel approaches to Parkinson's disease flowing into the drug development pipeline by allowing researchers to pursue their most exciting ideas in real time. The Foundation accepts Rapid Response proposals on a rolling basis with no deadline, and funding decisions are made within six weeks of application. Awards of up to $75,000 are available for one-year basic, preclinical or clinical research projects in any Parkinson's-relevant arena. The program has met with an enthusiastic response from the research community, both within Parkinson's disease and beyond, since it was first launched in January 2007.

"Rapid Response infuses capital quickly into exciting new ideas that could open up important new avenues of inquiry for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation. "Our goal is to provide the funding needed to further 'build the case' for these new concepts, developing the data required before other traditional funding sources can step in."

The program's application process and funding criteria emphasize speed and novelty. Funded projects typically are strong ideas being tested for the first time. Unlike other Foundation initiatives, Rapid Response allows for the submission of applications at any time of year. There is no pre-proposal triage stage, and the standard MJFF application has been shortened to three pages. Additionally, postdoctoral researchers are permitted to apply as principal investigators provided the head of their lab serves as administrative PI.

Among the potentially high-impact Rapid Response projects funded so far this year:

  • Asa Abeliovich, MD, PhD, of Columbia University is working to determine whether a gene silencing technique using microRNAs short, noncoding molecules of RNA can be effective in reducing alpha-synuclein, a protein whose aggregation, or clumping, in the brain is a hallmark of Parkinson's pathology.
  • Jian Feng, PhD, of SUNY-Buffalo, and Patrick Alfryn Lewis, PhD, of the Institute of Neurology (London, UK) and John A. Hardy, PhD, University College London (London, UK) are conducting two separate investigations using newly discovered induced pluripotent stem cell (iPS) technology to shed greater light on the Parkinson's-implicated genes parkin and LRRK2. Using iPS, the teams are engineering stem cells from skin cells, then using these engineered stem cells to generate human dopamine neurons with or without mutations in the respective genes. Both projects seek to characterize disease mechanisms set off by genetic mutations and to create new models for testing therapeutic approaches that could prevent these events from occurring.
  • Rahul Srinivasan, MBBS, PhD, and Henry A. Lester, PhD, of the California Institute of Technology are working to better understand epidemiological findings that have consistently shown smoking may protect against PD. The researchers hope to elucidate the mechanisms by which nicotine may protect dopamine neurons through development and validation of a screening test for small molecules that could increase nicotine receptor expression in the brain.
  • Marcus Unger, MD, and Wolfgang Oertel, MD, of Phillips University (Marburg, Germany) want to find better treatments for the digestive problems that dramatically affect Parkinson's patients' quality of life, as well as test the Braak hypothesis, which posits that Parkinson's disease progresses through the body and to the brain in a series of stages starting in the gastrointestinal system. They are examining a possible link between constipation and Lewy body pathology in the gastric lining of people with PD.


'/>"/>

Contact: Holly Barkhymer
hbarkhymer@michaeljfox.org
212-509-0995 x242
The Michael J. Fox Foundation for Parkinson's Research
Source:Eurekalert

Related biology news :

1. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
2. Neuroscientist Michael Gazzaniga awarded Humboldt Prize
3. Remarks Prepared for Delivery By Attorney General Michael B. Mukasey At the Ministerial Press Conference
4. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
5. American Society for Microbiology honors Michael Bruce Zwick
6. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
7. W.M. Keck Foundation grant funds reproductive science research
8. W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
9. Glenn Foundation for Medical Research commits $5 million to study aging
10. BBVA Foundation Awards for Biodiversity Conservation
11. The Parkinsons Disease Foundation awards $950,000 in seed grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today provided an update on the Company,s cases ... Texas and announcing that those ... Re-examination ("IPR") proceedings that VTech and Uniden filed ... on only certain claims of two of the patents ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... Mass. , Feb. 3, 2016  Silk Therapeutics, Inc., ... financing round. Silk Therapeutics has now raised a total of ... made by the company. The Series A2 round was led ... Massachusetts , with participation from new investors Lear Corporation ... Sheri and Roy P. Disney ; Richard Sackler , ...
Breaking Biology Technology: